PSMA PET/CT在新诊断的高危中危前列腺癌患者中的适用性——基于肿瘤体积的风险分层
The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification.
作者信息
Hagens Marinus J, Luining Wietske I, Boevé Liselotte M S, Knol Remco J J, Roeleveld Ton A, Srbljin Sandra, Weltings Saskia, Koppes Jose C C, Oprea-Lager Daniela E, Vis André N, van Leeuwen Pim J, van der Poel Henk G
机构信息
Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NCI-AVL), Amsterdam, The Netherlands.
Department of Urology, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands.
出版信息
Prostate Cancer Prostatic Dis. 2024 Sep 23. doi: 10.1038/s41391-024-00899-9.
BACKGROUND/OBJECTIVES: This study reassesses the diagnostic value of PSMA PET/CT in unfavorable intermediate-risk prostate cancer (PCa) and validates the Prostate Cancer Network the Netherlands (PCNN) subclassification.
SUBJECTS/METHODS: Men subjected to PSMA PET/CT were analyzed, evaluating the incidence of metastatic disease and its correlation with PCNN subgroups.
RESULTS
Metastatic disease was identified in 12.4% of patients. Higher PCNN subgroups correlated with increased metastatic potential; odds were significantly lower in low metastatic potential cases (OR: 0.19, 95% CI 0.06-0.62; p = 0.01).
CONCLUSIONS
Our findings reaffirm PSMA PET/CT's diagnostic value in unfavorable intermediate-risk PCa and validate the PCNN subclassification, reducing scan burden by 48.1%.
背景/目的：本研究重新评估了PSMA PET/CT在高危中危前列腺癌（PCa）中的诊断价值，并验证了荷兰前列腺癌网络（PCNN）的分类。
受试者/方法：对接受PSMA PET/CT检查的男性进行分析，评估转移疾病的发生率及其与PCNN亚组的相关性。
结果
12.4%的患者被发现有转移疾病。PCNN亚组越高，转移潜能越高；低转移潜能病例的几率显著更低（OR：0.19，95%CI 0.06 - 0.62；p = 0.01）。
结论
我们的研究结果再次证实了PSMA PET/CT在高危中危PCa中的诊断价值，并验证了PCNN分类，扫描负担降低了48.1%。
Zotero 插件